Emmanuel Gyan

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6057356/emmanuel-gyan-publications-by-year.pdf

Version: 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

95
papers

3,305
citations

4,056
ext. papers

29
h-index

56
g-index

4.21
L-index

#	Paper	IF	Citations
95	A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. <i>Blood</i> , 2021 , 137, 2646-2656	2.2	10
94	Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1700-1709	4.4	1
93	No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades. <i>British Journal of Haematology</i> , 2021 , 194, 635-638	4.5	1
92	Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study. <i>American Journal of Hematology</i> , 2021 , 96, 823-833	7.1	4
91	Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA <i>Journal of Clinical Oncology</i> , 2021 , 39, 7544-7544	2.2	1
90	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. <i>Blood</i> , 2021 , 137, 751-	7 <u>6</u> .2	77
89	Automated Early Detection of Myelodysplastic Syndrome within the General Population Using the Research Parameters of Beckman-Coulter DxH 800 Hematology Analyzer. <i>Cancers</i> , 2021 , 13,	6.6	1
88	Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. <i>Leukemia</i> , 2021 , 35, 2332-2345	10.7	О
87	Megaloblastic anemia-related iron overload and erythroid regulators: a case report. <i>Journal of Medical Case Reports</i> , 2021 , 15, 463	1.2	O
86	Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in FL from 5,225 Patients on 13 Clinical Trials. <i>Blood</i> , 2021 ,	2.2	6
85	Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group. <i>Hematological Oncology</i> , 2020 , 38, 446-455	1.3	O
84	Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma. <i>Blood</i> , 2020 , 135, 1811-1815	2.2	6
83	Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1076-1084	4.4	8
82	Survival Trends over 18 Years of Patients with Multiple Myeloma Harboring Del(17p) and/or t(4;14): A Retrospective Real-World Study. <i>Blood</i> , 2020 , 136, 15-17	2.2	
81	Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Final Results from the LyMa-MRD Project, Conducted on Behalf of	2.2	1
8o	Meta-analysis of case-control studies to examine the relationship between occupational pesticide exposure and risk of acute myeloid leukemia <i>Journal of Clinical Oncology</i> , 2020 , 38, 7540-7540	2.2	
79	Clonal hematopoiesis in the bone marrow and blood of healthy volunteers <i>Journal of Clinical Oncology</i> , 2020 , 38, 7517-7517	2.2	

(2018-2020)

78	Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells. <i>Oncogene</i> , 2020 , 39, 1198-1212	9.2	15
77	Hypercalcemia is associated with a poor prognosis in lymphoma a retrospective monocentric matched-control study and extensive review of published reported cases. <i>Annals of Hematology</i> , 2020 , 99, 229-239	3	5
76	Involvement of GPx-3 in the Reciprocal Control of Redox Metabolism in the Leukemic Niche. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	6
75	High prevalence of clonal hematopoiesis in the blood and bone marrow of healthy volunteers. <i>Blood Advances</i> , 2020 , 4, 3550-3557	7.8	15
74	Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature. <i>Blood Advances</i> , 2020 , 4, 5322-5335	7.8	1
73	Reactive oxygen species levels differentiate CD34 human progenitors based on CD38 expression. <i>Cytometry Part B - Clinical Cytometry</i> , 2020 , 98, 516-521	3.4	2
72	Characteristics, combinations, treatments, and survival of second primary hematological neoplasm: a retrospective single-center cohort of 49 patients (Hemostudy). <i>Annals of Hematology</i> , 2019 , 98, 2367-	2377	O
71	A variant erythroferrone disrupts iron homeostasis in -mutated myelodysplastic syndrome. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	27
70	Allogeneic Stem Cell Transplantation in Therapy-Related Myelodysplasia after Autologous Transplantation for Lymphoma: A Retrospective Study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2366-237	4·7 4	O
69	Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes. <i>Blood Advances</i> , 2019 , 3, 4271-4279	7.8	15
68	Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. <i>Haematologica</i> , 2019 , 104, 497-504	6.6	7
67	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018 , 132, 49-58	2.2	90
66	Endogenous Metabolites-Mediated Communication Between OAT1/OAT3 and OATP1B1 May Explain the Association Between SLCO1B1 SNPs and Methotrexate Toxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 687-698	6.1	20
65	Prospective evaluation of the effect of deferasirox on hematologic response in transfusion-dependent patients with low-risk MDS and iron overload. <i>European Journal of Haematology</i> , 2018 , 101, 165	3.8	4
64	Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. <i>Lancet Oncology, The</i> , 2018 , 19, 747-757	21.7	281
63	R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. <i>Blood</i> , 2018 , 131, 174-181	2.2	78
62	Glycemic dysregulation in a patient with type 2 diabetes treated with 5-azacitidine: a case report. Journal of Medical Case Reports, 2018 , 12, 199	1.2	4
61	Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study. <i>British Journal of Haematology</i> , 2018 , 183, 76-86	4.5	10

60	n-3 Polyunsaturated fatty acids induce acute myeloid leukemia cell death associated with mitochondrial glycolytic switch and Nrf2 pathway activation. <i>Pharmacological Research</i> , 2018 , 136, 45-5.	5 ^{10.2}	17
59	Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group. <i>Blood</i> , 2018 , 132, 2846-2846	2.2	
58	Benefits and pitfalls of pegylated interferon-2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. <i>Haematologica</i> , 2018 , 103, 438-446	6.6	30
57	Endogenous metabolites that are substrates of organic anion transporter's (OATs) predict methotrexate clearance. <i>Pharmacological Research</i> , 2017 , 118, 121-132	10.2	18
56	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. <i>Journal of Clinical Oncology</i> , 2017 , 35, 552-560	2.2	69
55	Alteration Analysis of Bone Marrow Mesenchymal Stromal Cells from De Novo Acute Myeloid Leukemia Patients at Diagnosis. <i>Stem Cells and Development</i> , 2017 , 26, 709-722	4.4	25
54	Consolidation anti-CD22 fractionated radioimmunotherapy with Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. <i>Lancet Haematology,the</i> , 2017 , 4, e35-e45	14.6	23
53	Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses. <i>Oncotarget</i> , 2017 , 8, 41876-41889	3.3	21
52	Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. <i>Oncotarget</i> , 2016 , 7, 85573-85583	3.3	8
51	Midostaurin in Advanced Systemic Mastocytosis. <i>New England Journal of Medicine</i> , 2016 , 374, 2605-7	59.2	40
50	Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a "Proof of Concept" Phase II Study of the French LOC Network. <i>Blood</i> , 2016 , 128, 785-785	2.2	35
49	Refractory thrombocytopenia and neutropenia: a diagnostic challenge. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015 , 7, e2015018	3.2	6
48	An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes. <i>Leukemia Research Reports</i> , 2014 , 3, 58-6	p.6	67
47	Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 329-42	3.8	13
46	Interferon alpha with or without rituximab achieves a high response rate and durable responses in relapsed FL: 17 years' experience in a single centre. <i>Annals of Hematology</i> , 2014 , 93, 147-156	3	4
45	Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. <i>Annals of Hematology</i> , 2014 , 93, 233-42	3	17
44	Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia. <i>British Journal of Haematology</i> , 2014 , 166, 390-400	4.5	45
43	Could a citrus keep the haematologist away?. British Journal of Haematology, 2014 , 166, 298-300	4.5	1

42	Prospective Analysis of the Quality of Life of Chronic Phase CML Patients on Second Generation Tyrosine Kinase Inhibitors after Imatinib Failure. an Observational Study. <i>Blood</i> , 2014 , 124, 1321-1321	2.2	2
41	High Efficiency and Tolerance of Temozolomide in Relapse/Refractory Primary Intra-Ocular Lymphoma (R/R PIOL). a Retrospective Multicentric Study from the LOC Network. <i>Blood</i> , 2014 , 124, 308	3 0-3 08	0
40	Mast Cell Disease and Blood Coagulation Abnormalities: Discussion on 14 Cases and Review of the Literature. <i>Blood</i> , 2014 , 124, 2856-2856	2.2	
39	A stability-indicating, ion-pairing, reversed-phase liquid chromatography method for studies of daunorubicin degradation in i.v. infusion fluids. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013 , 83, 164-70	3.5	6
38	High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. <i>Annals of Hematology</i> , 2013 , 92, 621-31	3	34
37	Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2920-6	2.2	124
36	Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2399-404	1.9	23
35	Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients. <i>British Journal of Haematology</i> , 2013 , 162, 413-5	4.5	21
34	High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. <i>British Journal of Haematology</i> , 2013 , 162, 240-9	4.5	8
33	Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA. <i>Annals of Oncology</i> , 2013 , 24, 2612-2618	10.3	27
32	Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 104-10	2.2	115
31	Efficacy and safety of pegylated-interferon P2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. <i>British Journal of Haematology</i> , 2013 , 162, 783-91	4.5	55
30	A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. <i>Haematologica</i> , 2013 , 98, 881-7	6.6	58
29	Flow cytometric quantification of all phases of the cell cycle and apoptosis in a two-color fluorescence plot. <i>PLoS ONE</i> , 2013 , 8, e68425	3.7	58
28	Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. <i>Blood</i> , 2012 , 119, 1532-42	2.2	47
27	Epidermotropic secondary cutaneous involvement by relapsed angioimmunoblastic T-cell lymphoma mimicking mycosis fungoides: a case report. <i>Journal of Cutaneous Pathology</i> , 2012 , 39, 1119-	247	10
26	Usefulness of corticosteroid therapy during chronic disseminated candidiasis: case reports and literature review. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 1493-5	5.1	21
25	Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. <i>Clinical Cancer Research</i> , 2012 , 18, 5203-11	12.9	170

24	A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. <i>Haematologica</i> , 2012 , 97, 1085-91	6.6	85
23	Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 935-40	4.7	6
22	Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. <i>Blood</i> , 2011 , 118, 4338-45	2.2	91
21	Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. <i>Haematologica</i> , 2011 , 96, 1128-35	6.6	84
20	Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3194-200	2.2	148
19	MEhylation et syndromes mylbdysplasiques. <i>Hematologie</i> , 2010 , 16, 12-16	O	
18	Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica, 2010 , 95, 1350-7	6.6	34
17	Bone Marrow Mesenchymal Stromal Cells Regulate the Metabolism of H2O2 In Human Leukemic Cells <i>Blood</i> , 2010 , 116, 1058-1058	2.2	
16	High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. <i>Blood</i> , 2009 , 113, 995-1001	2.2	116
15	Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum. <i>Leukemia</i> , 2008 , 22, 1864-73	10.7	20
14	Apoptotic pathways to death in myelodysplastic syndromes. <i>Haematologica</i> , 2008 , 93, 1288-92	6.6	6
13	Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial. <i>Haematologica</i> , 2007 , 92, 1623-30	6.6	24
12	Caspase-8 prevents sustained activation of NF-kappaB in monocytes undergoing macrophagic differentiation. <i>Blood</i> , 2007 , 109, 1442-50	2.2	104
11	Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. <i>New England Journal of Medicine</i> , 2007 , 357, 1916-27	59.2	324
10	Reply to 'hRap1B-retro: a novel human processed Rap1B gene blurs the picture?' by Zemojtel et al. <i>Leukemia</i> , 2006 , 20, 146-147	10.7	5
9	Mitochondria in hematopoiesis and hematological diseases. <i>Oncogene</i> , 2006 , 25, 4757-67	9.2	68
8	Mutation in RAP1 is a rare event in myelodysplastic syndromes. <i>Leukemia</i> , 2005 , 19, 1678-80	10.7	13
7	Pseudouveitis: a clue to the diagnosis of primary central nervous system lymphoma in immunocompetent patients. <i>Medicine (United States)</i> , 2004 , 83, 223-232	1.8	9

LIST OF PUBLICATIONS

6	Rituximab therapy for HIV-associated Castleman disease. <i>Blood</i> , 2003 , 102, 2786-8	2.2	126
5	Primary central nervous system lymphoma in immunocompetent adults: poor results mainly associated with high treatment related toxicities. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1819-22	1.9	6
4	Pit2 assemblies at the cell surface are modulated by extracellular inorganic phosphate concentration. <i>Journal of Virology</i> , 2002 , 76, 4304-11	6.6	28
3	p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2001 , 98, 244-6	2.2	70
2	Prognostic significance of p16INK4a immunocytochemistry in adult ALL with standard risk karyotype. <i>Leukemia</i> , 2001 , 15, 1054-9	10.7	7
1	Acute priapism in a patient with unstable hemoglobin Perth and Factor V Leiden under effective oral anticoagulant therapy. <i>The Hematology Journal</i> , 2001 , 2, 210-1		14